With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or ...

Biliary Tract Cancer (BTC): KEYTRUDA may be combined with chemotherapy medicines to treat BTC, a cancer that affects the bile ducts or gallbladder. This treatment is for adults when the cancer has ...

Personalized Cancer Vaccines Ecosystem Witnessing Positive Transition Driven By Development Of Proprietary Technology Platforms Says Kuick Research. Delhi, March 2 ...

T he phase 3 KEYNOTE-355 trial (NCT02819518) demonstrated that in patients with advanced TNBC whose tumors expressed PD-L1 with a combined positive score (CPS) of 10 or more, adding pembrolizumab ...

Cost: Branded Viagra is priced at $96 per dose regardless of the milligram dosage, and you can work with your prescriber to find the dosage that’s right for you. Sildenafil is also available ...

Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent dispute, according to a report by The Wall Street Journal on Wednesday.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

Merck’s (NYSE:MRK) injectable based on an enzyme developed by South Korea-based Alteogen is the company’s answer to the upcoming patent cliff for intravenously delivered Keytruda, which ...

A dispute over a microscopic enzyme is threatening Merck & Co. plans to sell a new version of Keytruda, the cancer drug that generates nearly half of the company’s sales. Merck has been tweaking ...

March 5 (Reuters) - Merck's (MRK.N), opens new tab injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics (HALO.O ...

The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that convert intravenous drugs into injectable versions. An investigational ...